ALLO

Business Context and Reporting Period

Company: Allogene Therapeutics, Inc. (ALLO)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: Allogene is a clinical-stage immuno-oncology company developing genetically engineered allogeneic ("off-the-shelf") T cell product candidates for cancer and autoimmune diseases. The company focuses on three core clinical programs: ALPHA3 (cema-cel for large B-cell lymphoma), TRAVERSE (ALLO-316 for renal cell carcinoma), and RESOLUTION (ALLO-329 for autoimmune diseases).

Key Financial Metrics

Note: Revenue is derived solely from collaboration agreements; no product sales have been made.

Material Changes vs. Prior Period

• Reduced Net Loss: Net loss decreased by 38% in Q3 2025 compared to Q3 2024, and by 23% for the nine-month period. This improvement is primarily driven by significant reductions in operating expenses.
• Operating Expense Reduction: Total operating expenses declined 37% in Q3 and 22% in the nine-month period year-over-year.
  • R&D Expenses: Decreased $13.5M in Q3 and $25.8M in 9M, driven by lower personnel costs (including stock-based compensation) and development costs.
  • G&A Expenses: Decreased $2.6M in Q3 and $6.7M in 9M, primarily due to reduced personnel costs.
• Impairment Charges: Q3 2024 included a $10.7M impairment charge for long-lived assets related to subleased properties. Q3 2025 had no such charge. For the nine months ended Sept 30, 2025, impairment charges were $2.4M (down from $15.7M in 2024), consisting of $1.0M for subleased property and $1.3M for equipment related to workforce reduction.
• Workforce Reduction: In May 2025, the company executed a ~28% workforce reduction to reprioritize resources toward clinical programs. This resulted in approximately $3.3M in cash-based severance and benefit costs recognized in the nine months ended Sept 30, 2025.
• Liquidity Position: Total cash, cash equivalents, and investments decreased from $373.1M at Dec 31, 2024, to $277.1M at Sept 30, 2025, reflecting operational cash burn and investment maturities.

Guidance, Outlook, and Risks

• Clinical Trial Updates:
  • ALPHA3 (cema-cel): The trial was amended to remove the FCA arm (fludarabine, cyclophosphamide, and ALLO-647) following a Grade 5 adverse event (hepatic failure) attributed to ALLO-647. The trial now proceeds with a two-arm design comparing cema-cel with standard FC lymphodepletion to observation. A futility analysis is expected in the first half of 2026.
  • TRAVERSE (ALLO-316): Enrollment of 20 patients in the Phase 1b expansion cohort is complete. The company has received RMAT designation and believes it has aligned with the FDA on a registration trial design.
  • RESOLUTION (ALLO-329): Initiated in Q2 2025 for autoimmune diseases. Proof-of-concept data is anticipated in the first half of 2026.
• Capital Resources: Management expects current cash and investments ($277.1M) to fund operations into the second half of 2027. The company anticipates continuing to incur net losses and will need to raise additional capital in the future.
• Key Risks:
  • Intellectual Property Litigation: Factor Bioscience filed a lawsuit against Cellectis (Allogene's TALEN technology licensor) alleging patent infringement. If Cellectis loses, Allogene may lose access to critical gene-editing technology for cema-cel and ALLO-316.
  • Regulatory & Safety: Uncertainty regarding the efficacy of the FC-only lymphodepletion regimen in the ALPHA3 trial. Potential delays in regulatory approval of the companion diagnostic (MRD assay) required for patient selection.
  • Manufacturing: Reduced manufacturing operations following the workforce reduction may limit operational readiness and require requalification if ramped up in the future.

Investor Verification Checklist

• Cash Runway: Verify the sustainability of the "second half of 2027" cash runway estimate given the current burn rate and potential for increased clinical costs.
• ALPHA3 Trial Design: Confirm the impact of removing the ALLO-647 arm on the statistical power and timeline of the cema-cel registration path.
• IP Litigation Status: Monitor the Factor Bioscience vs. Cellectis litigation, as a negative outcome could jeopardize the core oncology pipeline.
• Companion Diagnostic: Assess the regulatory progress of Foresight Diagnostics' MRD assay, which is critical for the ALPHA3 trial and potential commercialization.
• Manufacturing Capacity: Evaluate the long-term implications of the 28% workforce reduction on the ability to scale manufacturing for commercial launch.